Clinical and Epidemiological Evaluation of Patients With Traumatic and Hypoxic-ischemic Brain Injury

What this Trial Is About

Perinatal asphyxia is a leading cause of severe neurological disabilities and neonatal death, affecting newborns worldwide with varying incidence rates. This condition results in neonatal hypoxic-ischemic encephalopathy, characterized by altered consciousness, seizures, and breathing difficulties in infants born after 35 weeks of gestation. Additionally, traumatic brain injury (TBI) is a major cause of illness and death in children and young adults, with neuroinflammation playing a key role in both acute and long-term brain damage. Current treatments for these brain injuries are limited, highlighting the urgent need for new therapies with broader therapeutic windows to better protect neurological tissue. The study observes patients aged 0 to 20 years who have brain damage from severe traumatic brain injury or perinatal asphyxia. It evaluates neurological function and disability through clinical assessments, including the Gross Motor Function Classification System. The trial does not involve experimental treatments but focuses on monitoring and assessing participants' neurological outcomes over time. Participants undergo evaluations at least two years after their brain injury, including assessments of motor function, muscle tone, disability, quality of life, communication abilities, and overall disability inventory. These evaluations help researchers understand the long-term effects of traumatic and hypoxic-ischemic brain injuries. The study collects data to improve knowledge about these conditions and potential future therapeutic approaches, with the total participation duration extending to two years or more.

Evaluation of Patients Affected by Traumatic and Hypoxic-ischemic Brain Injury